A randomized, double-blind, placebo-, and positive-controlled clinical pilot study to evaluate the efficacy and tolerability of standardized aqueous extracts of Terminalia chebula and Terminalia bellerica in subjects with hyperuricemia.

At the end of 4 weeks of treatment, when the absolute change in serum uric acid levels was compared among the five treatment groups, it was found to be highly significant for T. chebula 500 mg (A) versus febuxostat (D), T. bellerica 500 mg (B) versus placebo (E), T. bellerica 250 mg (C) versus febuxostat (D), and febuxostat (D) versus placebo (E), with a P -value <0.001.

also in 132,142 other papers